NEUTROPHIL-TO-LYMPHOCYTE RATIO AND BLOOD PLATELET COUNT CAN BE PROGNOSTIC MARKERS IN ACUTE RESPIRATORY DISTRESS SYNDROME PATIENTS OF DIFFERENT IMMUNE STATES

Abstract Rebamipide has a noteworthy potential as an adjunct therapy of coronavirus disease (COVID-19) which may act as an anti- IL8. There have been no yet previous studies declared worldwide examining the use of it. We conducted a study of Rebamipide through the secondary data obtained from the medical record then analyzed the neutrophile, lymphocytes, and neutrophil-lymphocyte ratio of patients. Our data exhibited improvements in the laboratory outcomes, revealing decreased neutrophils, increased lymphocytes, also increased neutrophil-lymphocyte rations, observed in COVID-19 patients experiencing acute respiratory distress syndrome (ARDS).

Download Full-text

Monocyte-to-lymphocyte ratio is associated with 28-day mortality in patients with acute respiratory distress syndrome: a retrospective study

Journal of Intensive Care ◽

10.1186/s40560-021-00564-6 ◽

2021 ◽

Vol 9 (1) ◽

Author(s):

Lijuan Yang ◽

Chang Gao ◽

Fengyuan Li ◽

Ling Yang ◽

Jiahao Chen ◽

...

Keyword(s):

Acute Respiratory Distress Syndrome ◽

Respiratory Distress Syndrome ◽

Respiratory Distress ◽

Distress Syndrome ◽

Area Under The Curve ◽

Distribution Width ◽

Albumin Ratio ◽

Inflammatory Biomarker ◽

Lymphocyte Ratio ◽

The Relationship

Abstract Background Systemic inflammation relates to the initiation and progression of acute respiratory distress syndrome (ARDS). Neutrophil-to-lymphocyte ratio (NLR) and red blood cell distribution width (RDW)/albumin ratio have been reported to be predictive prognostic biomarkers in ARDS patients. However, the role of monocyte-to-lymphocyte ratio (MLR) as a prognostic inflammatory biomarker in a variety of diseases is rarely mentioned in ARDS. In this study, we explored the relationship between MLR and disease severity in ARDS patients and compared it with other indicators associated with 28-day mortality in patients with ARDS. Methods We retrospectively included 268 patients who fulfilled the Berlin definition of ARDS and were admitted to a single institute from 2016 to 2020. Clinical characteristics and experimental test data were collected from medical records within 24 h after the ARDS diagnosis. MLR, NLR, and RDW/albumin ratio levels were calculated. The primary clinical outcome was 28-day mortality. Logistic regression analysis was used to illustrate the relationship between indicators and 28-day mortality. Receiver operating characteristic (ROC) curve was used to evaluate the area under the curve (AUC), and propensity score matching (PSM) was employed to validate our findings. Results The median MLR values were higher for non-survivors than for survivors before and after matching (P<0.001, P=0.001, respectively). MLR values were significantly associated with 28-day mortality (OR 2.956; 95% CI 1.873–4.665; P<0.001). MLR and NLR indicators were combined for predictive efficacy analysis, and its AUC reached 0.750. There was a significant increase in 28-day mortality depending on the increasing MLR level: low MLR group 38 (20.4%), high MLR group 47 (57.3%) (P<0.001). Conclusions Higher MLR values were associated with 28-day mortality in patients with ARDS. Further investigation is required to verify this relationship with prospectively collected data.

Download Full-text